COMPANY PROFILE

Thyas

Explore full profile

Uses ips cell technology to develop cancer treatments

Kyoto, JapanFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Thyas

Thyas Co., Ltd. is a pioneering biotechnology company specializing in the development of advanced T cell immunotherapy solutions. The company focuses on utilizing induced pluripotent stem cells (iPSCs) to create personalized and off-the-shelf T cell therapies aimed at treating various forms of cancer. Thyas operates in the biomedical sector, serving healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the research, development, and commercialization of cutting-edge immunotherapy treatments. Revenue is generated through partnerships, licensing agreements, and direct sales of their proprietary therapies. The company is led by a team of experts in the fields of medicine, biology, and business, ensuring a robust and innovative approach to cancer treatment.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Kyoto, Japan
Employees: 3
Open positions: None listed
Dealroom signal: 61.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Feb 2022	$16M	$66M	Undisclosed	—
SERIES AEquity / VC	Oct 2021	$2.7M	$11M	Kyoto University Innovation Capital · D3	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Thyas website traffic

Latest recorded traffic for Thyas is 140 monthly website visits, up 16.7% over the last three months. Thyas's team declined 25% over the past year.

Latest monthly visits140 3-month web change+16.7% 1-year team growth-25%

Monthly website visitsJan 2022–Jun 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
SPSpireaAdvanced antibody-drug conjugate technology for cancer therapeutics	Harrogate, United Kingdom	Operational
VTValo TherapeuticsAn immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines	Helsinki, Finland	Operational
EBEisbach BioInnovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes	Planegg, Germany	Operational